Mutational monitoring of EGFR T790M in cfDNA for clinical outcome prediction in EGFR-mutant lung adenocarcinoma

Схожие документы

• The emergence of T790M mutation in EGFR-mutant lung adenocarcinoma patients having a history of acquired resistance to EGFR-TKI: focus on rebiopsy timing and long-term existence of T790M
  по: Tseng, Jeng-Sen, et al.
  Опубликовано: (2016)
• The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M
  по: Huang, Yen-Hsiang, et al.
  Опубликовано: (2021)
• Primary Tumor Radiotherapy During EGFR-TKI Disease Control Improves Survival of Treatment Naïve Advanced EGFR-Mutant Lung Adenocarcinoma Patients
  по: Hsu, Kuo-Hsuan, et al.
  Опубликовано: (2021)
• Prior EGFR tyrosine-kinase inhibitor therapy did not influence the efficacy of subsequent pemetrexed plus platinum in advanced chemonaïve patients with EGFR-mutant lung adenocarcinoma
  по: Tseng, Jeng-Sen, et al.
  Опубликовано: (2014)
• The Association of Acquired T790M Mutation with Clinical Characteristics after Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma
  по: Huang, Yen-Hsiang, et al.
  Опубликовано: (2018)